Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | SQLE | Q14534 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8940810 | 1.00 | KMT2A (0.64) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL4307163 | 0.98 | KMT2A (0.60) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL806716 | 0.98 | KMT2A (0.60) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL28814759 | 0.86 | KMT2A (0.45) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL23458530 | 0.86 | KMT2A (0.52) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL23458529 | 0.86 | KMT2A (0.52) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10000157 | 0.83 | KMT2A (0.64) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL20510124 | 0.83 | KMT2A (0.64) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10000172 | 0.83 | KMT2A (0.64) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10544495 | 0.83 | KMT2A (0.64) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059636-A1 | PROCESS OF MAKING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-02-22 | — | — | US | disclosed |
| WO-2022136227-A1 | PROCESS OF MAKING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-20210282678-A1 | DEVICE AND METHODS FOR DETECTION AND MONITORING OF TUBERCULOSIS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2021-09-16 | — | — | US | disclosed |
| EP-3000464-B1 | COMPOSITION COMPRISING FARNESOL AND USE THEREOF | DAEGU GYEONGBUK INST SCIENCE & TECH (KR) | 2020-05-06 | — | — | EP | disclosed |
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-08-28 | — | — | US | disclosed |
| US-8153826-B2 | Process for production of (±)-3a,6,6,9a-Tetramethyldecahydronaphtho[2,1-b]Furan-2(1H)-one | KAO CORPORATION (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153826-B2 | Process for production of (±)-3a,6,6,9a-Tetramethyldecahydronaphtho[2,1-b]Furan-2(1H)-one | KAO CORPORATION (JP) | 2012-04-10 | — | — | US | disclosed |
| WO-2012037069-A2 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20090270639-A1 | PROCESS FOR PRODUCTION OF (±)-3A,6,6,9A- TETRAMETHYLDECAHYDRONAPHTHO[2,1-B]FURAN-2(1H)-ONE | KAO CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270639-A1 | PROCESS FOR PRODUCTION OF (±)-3A,6,6,9A- TETRAMETHYLDECAHYDRONAPHTHO[2,1-B]FURAN-2(1H)-ONE | KAO CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2048139-A1 | PROCESS FOR PRODUCTION OF (±)-3a,6,6,9a TETRAMETHYLDECAHYDRONAPHTHO[2,1-b]FURAN-2(1H)-ONE | Kao Corporation (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | WEE1, WEE2, NOTUM | KMT2A 3869/4885ALOX15 161/4885MAPT 4714/4885 |
| US-20090270639-A1 | PROCESS FOR PRODUCTION OF (±)-3A,6,6,9A- TETRAMETHYLDECAHYDRONAPHTHO[2,1-B]FURAN-2(1H)-ONE | COASY, FASN, CYP2C9 | KMT2A 3960/4885ALOX15 136/4885MAPT 4477/4885 |
| US-20240059636-A1 | PROCESS OF MAKING ORGANIC COMPOUNDS | POR, CYC1, CYP11B1 | KMT2A 4192/4885ALOX15 144/4885MAPT 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.